Penelope J Hallett

List of Publications by Year in Descending Order

45 papers	3,143 citations	30 h-index	46 g-index
46 ext. papers	3,652 ext. citations	8.2 avg, IF	5.06 L-index

#	Paper	IF	Citations
45	Glycosphingolipid metabolism and its role in ageing and Parkinson's disease. *Glycoconjugate Journal*, **2021**, 1	3	2
44	Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2. *Molecular Brain*, **2021**, 14, 16	4.5	5
43	Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients. *Frontiers in Cellular Neuroscience*, **2020**, 14, 58	6.1	20
42	Cell type-specific lipid storage changes in Parkinson's disease patient brains are recapitulated by experimental glycolipid disturbance. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 27646-27654	11.5	17
41	Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson's disease genetic risk. *International Review of Neurobiology*, **2020**, 154, 279-302	4.4	3
40	Upregulating β-hexosaminidase activity in rodents prevents β-synuclein lipid associations and protects dopaminergic neurons from β-synuclein-mediated neurotoxicity. *Acta Neuropathologica Communications*, **2020**, 8, 127	7.3	6
39	Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice. *Molecular Therapy - Nucleic Acids*, **2020**, 21, 623-635	10.7	18
38	Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson's disease. *Journal of Neuroinflammation*, **2019**, 16, 153	10.1	39
37	Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts. *Human Molecular Genetics*, **2019**, 28, 3232-3243	5.6	30
36	Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. *Molecular Neurodegeneration*, **2019**, 14, 40	19	56
35	Novel Results and Concepts Emerging From Lipid Cell Biology Relevant to Degenerative Brain Aging and Disease. *Frontiers in Neurology*, **2019**, 10, 1053	4.1	12
34	Neurite Collapse and Altered ER Ca Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation. *Stem Cell Reports*, **2019**, 12, 29-41	8	33
33	Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. *Neurobiology of Aging*, **2018**, 67, 189-200	5.6	50
32	The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. *Neurobiology of Disease*, **2018**, 120, 1-11	7.5	39
31	Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age. *Scientific Reports*, **2018**, 8, 15207	4.9	19
30	Seq-ing Markers of Midbrain Dopamine Neurons. *Cell Stem Cell*, **2017**, 20, 11-12	18	5
29	Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition. *Molecular Neurobiology*, **2016**, 53, 5161-77	6.2	48

28	Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. *Cell Stem Cell*, **2015**, 16, 269-74	18	214
27	Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. *Antioxidants and Redox Signaling*, **2015**, 23, 550-64	8.4	79
26	Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. *Neurobiology of Disease*, **2015**, 82, 495-503	7.5	88
25	Progressive decline of glucocerebrosidase in aging and Parkinson's disease. *Annals of Clinical and Translational Neurology*, **2015**, 2, 433-8	5.3	122
24	A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C). *PLoS ONE*, **2015**, 10, e0121072	3.7	39
23	Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease. *Neurobiology of Disease*, **2014**, 64, 79-87	7.5	46
22	Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. *Human Molecular Genetics*, **2014**, 23, 4510-27	5.6	62
21	Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. *Cell Reports*, **2014**, 7, 1755-61	10.6	112
20	ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress. *Experimental Neurology*, **2014**, 261, 217-29	5.7	9
19	Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. *Neuroscience Letters*, **2014**, 576, 73-8	3.3	57
18	Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. *Stem Cells*, **2013**, 31, 1548-62	5.8	168
17	α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. *Neurobiology of Disease*, **2012**, 47, 258-67	7.5	68
16	Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. *Molecular and Cellular Neurosciences*, **2012**, 49, 230-9	4.8	35
15	Development of histocompatible primate-induced pluripotent stem cells for neural transplantation. *Stem Cells*, **2011**, 29, 1052-63	5.8	37
14	Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 15921-6	11.5	375
13	The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. *Journal of Neuroscience*, **2010**, 30, 16091-101	6.6	80
12	Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. *Synapse*, **2010**, 64, 177-80	2.4	61
11	PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. *Journal of Neuroscience*, **2009**, 29, 2948-60	6.6	61

10	No evidence for disease-like processes in fetal transplants. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, E104; author reply E105	11.5	2
9	Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 22474-9	11.5	41
8	The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies. *Neurobiology of Disease*, **2009**, 35, 348-51	7.5	26
7	Striatal histone modifications in models of levodopa-induced dyskinesia. *Journal of Neurochemistry*, **2008**, 106, 486-94	6	82
6	Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking. *Current Protocols in Neuroscience*, **2008**, Chapter 1, Unit 1.16	2.7	70
5	Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. *Nature Medicine*, **2008**, 14, 507-9	50.5	355
4	Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. *Movement Disorders*, **2007**, 22, 28-40	7	21
3	Inhibition of the dopamine D1 receptor signaling by PSD-95. *Journal of Biological Chemistry*, **2007**, 282, 15778-89	5.4	76
2	Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. *Journal of Neuroscience*, **2006**, 26, 4690-700	6.6	167
1	Rationale for and use of NMDA receptor antagonists in Parkinson's disease **2004**, 102, 155-74		187